Benefit and Timing of Second Transplantations in Multiple Myeloma: Clinical Findings and Methodological Limitations in a European Group for Blood and Marrow Transplantation Registry Study

Abstract

To improve survival of tandem autologous transplantation in multiple myeloma, the second transplantation should preferably be performed before relapse and within 6 to 12 months of the first transplantation.

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial

“…In a retrospective study, Morris et al 12 showed that a second ASCT performed before relapse and within 6 to 12 months of the first ASCT improved survival.…”

“…[6][7][8][9][10][11] Recently, a retrospective study has compared tandem ASCT up front with a strategy including planned second ASCT at relapse or progression. 12 In this retrospective study, Morris et al 12 showed that a second ASCT performed before relapse and within 6 to 12 months of the first ASCT improved survival.…”

Efficacy and outcome of autologous transplantation in rare myelomas

“…23 The complete remission rates in patients with this type of myeloma appear to be very high, both before and after transplantation, possibly because of the lack of an identifiable paraprotein. The progression-free survival of patients with non-secretory myeloma appears to be superior to that of patients with common myeloma (P=0.0003), but there was no difference in overall survival between the two groups.…”

Cure of multiple myeloma – more hype, less reality

“…A retrospective analysis by the EBMT registry suggested that the completion of a second HSCT before relapse and within 6-12 months of the first transplant resulted in superior outcomes. 94 The Arkansas group performed serial landmark analyses to define the optimal timing of a planned HSCT in TTI: 79 EFS and OS both were longer among the patients who had received a second HSCT within 12 months. Cure of multiple myeloma P Hari et al Cure and 'operational cure' There are no studies that demonstrate a plateau in the relapse curve for MM patients undergoing intense HDT.…”